“The ansuvimab-zykl nonclinical safety studies included a good laboratory practice (GLP) 4 week, intravenous, repeat-dose toxicology study in rhesus monkeys”
Rhesus monkey is the lethal EBOV challenge model used for proof of concept
“The activity of ansuvimab-zykl was evaluated in three in vivo proof-of-concept studies in which rhesus monkeys were challenged with uniformly lethal doses of Kikwit 8U EBOV (1000 pfu).”